Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases

We examine sex differences in relation to the nature, frequency, and burden of patient-reported adverse drug reactions (ADRs) in patients with inflammatory rheumatic diseases. Rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis patients using etanercept or adalimumab from the Dutch Biologic Monitor were sent bimonthly questionnaires concerning experienced ADRs. Sex differences in the proportion and nature of reported ADRs were assessed. Additionally, 5-point Likert-type scales reported for the burden of ADRs, were compared between sexes. In total 748 consecutive patients were included (59% female). From the women 55% reported ≥1 ADR, which was significantly higher than 38% of the men that reported ≥1 ADR (p

本研究旨在探讨与炎症性风湿病相关的患者报告的不良药物反应（ADRs）的性质、频率及负担，并分析性别差异。具体而言，纳入荷兰生物监测项目中的类风湿关节炎、银屑病关节炎或轴向强直性脊柱炎患者，使用依那西普或阿达木单抗治疗，并定期进行为期两月的问卷调查，以收集患者所经历的不良药物反应。本研究评估了报告中ADRs的比例和性质是否存在性别差异，并比较了不同性别对ADRs负担的5点李克特量表评分。总计纳入了748名连续患者（女性占59%）。其中，女性患者中有55%报告了≥1次ADRs，显著高于男性患者中的38%（p值未给出）。